Bankrupt biopharmaceutical business Dendreon Corp. is asking a Delaware bankruptcy judge to approve Valeant Pharmaceuticals International Inc. (NYSE: VRX, TSX: VRX) as the lead bidder for the debtor's prostate cancer treatment, Provenge, and other assets.

Seattle-based Denderon focuses on developing cancer-treatment products. Provenge was approved by the U.S. Food & Drug Administration in April 2010 to treat advanced-stage prostate cancer.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.